Tunlametinib (HL-085) is a highly selective and oral inhibitor of MEK1/2 with an IC50 of 1.9 nM for MEK1, with the potential to treat RAS/RAF mutant cancers. It also induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in a dose-dependent manner. It also exhibits antitumor activity in patients with advanced NRAS-mutant melanoma.
More Information Supplier PageACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.
More Information Supplier PageACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.
More Information Supplier PageACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.
More Information Supplier PageACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.
More Information Supplier PageNT-0796 is a brain-penetrant and highly potent inhibitor of NLRP3 Inflammasome with a potential for treating neuroinflammatory disorders. It inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM.
More Information Supplier PageNT-0796 is a brain-penetrant and highly potent inhibitor of NLRP3 Inflammasome with a potential for treating neuroinflammatory disorders. It inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM.
More Information Supplier PageNT-0796 is a brain-penetrant and highly potent inhibitor of NLRP3 Inflammasome with a potential for treating neuroinflammatory disorders. It inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM.
More Information Supplier PageNT-0796 is a brain-penetrant and highly potent inhibitor of NLRP3 Inflammasome with a potential for treating neuroinflammatory disorders. It inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM.
More Information Supplier PageART899, a derivative of ART558 is a potent, specific allosteric inhibitor of DNA polymerase theta (Polθ), specifically inhibits Polθ MMEJ activity with IC50 of 180 nM. It specifically radiosensitizes tumor cells and have a potent stand-alone antitumor effect in cancer cells.
More Information Supplier Page
